NYSE:RBOT
Vicarious Surgical Inc.
A clinical-stage robotics company developing autonomous surgical platforms to democratize access to high-end surgical care through remote telesurgery capabilities.
Key Metrics
Investment Thesis
Bull Case
Vicarious Surgical represents a high-risk, high-reward opportunity in the emerging autonomous robotics sector with potential to disrupt traditional surgical care models. If the company successfully navigates regulatory hurdles and achieves commercial validation, the first-mover advantage in fully autonomous telesurgery could create an uncontested market leader position. The massive cash runway depletion suggests urgency for capital raises that may dilute existing shareholders but validates continued technological progress by experienced management.
Bear Case
The company's financial health is precarious with a retained earnings deficit of $-195.9M and cash on hand insufficient to cover annual burn rates without immediate external financing. Operating losses exceeding $60M annually and zero revenue indicate the product is not yet commercially viable or scalable for mass market adoption. Investors are exposed to total capital loss risk as the company has no profitable operations and relies entirely on non-operating income and asset liquidation to survive.
About Vicarious Surgical Inc.
Vicarious Surgical designs and manufactures autonomous robotic surgical systems that enable remote telesurgery and minimally invasive procedures. The company primarily serves hospitals and ambulatory surgery centers in the United States, with its flagship platform capable of performing complex surgeries across various specialties including orthopedics, urology, and general surgery.
Analysis
Management Discussion
Financial performance in 2024 shows a net loss of $63.2M, consistent with the $-71.1M loss in 2023, indicating sustained heavy investment in R&D totaling $40.2M annually. Cash reserves have decreased significantly from $53.8M at the beginning of the period to $10.7M at year-end due to a net cash outflow of $43.1M, primarily driven by investing activities and operational burn. While interest income of $3.3M provides some offset, the company remains highly dependent on capital markets or strategic financing to fund operations until product revenue materializes.
Industry Overview
The global surgical robotics market is experiencing rapid growth driven by aging demographics and the demand for minimally invasive procedures, yet competition from established players like Intuitive Surgical dominates current revenue streams. Regulatory environments in healthcare are stringent, requiring extensive clinical trials and FDA approval before autonomous systems can be deployed widely. The industry is shifting towards cost-effective solutions that can operate without constant surgeon supervision to reduce procedure costs and expand access.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $80.1M | $80.7M | $66.6M |
| Operating Income | $-80.1M | $-80.7M | $-66.6M |
| R&D | $43.9M | $47.6M | $40.2M |
| G&A | $29.7M | $26.9M | $21.9M |
| Marketing | $6.5M | $6.2M | $4.5M |
| Stock-Based Comp | $12.3M | $13.3M | $11.9M |
| Depreciation | $1.1M | $1.9M | $2.1M |
| Other OpEx | $0 | $-2.1M | $0 |
| Non-Operating Income | $85.2M | $9.6M | $3.3M |
| Interest Expense | $200.0K | $25.0K | — |
| Interest Income | $1.4M | — | $3.3M |
| Pre-Tax Income | $5.2M | $-71.1M | $-63.2M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $5.2M | $-71.1M | $-63.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $5.2M | $-71.1M | $-63.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $5.2M | $-71.1M | $-63.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $120.4M | $101.0M | $51.7M |
| Cash & Equivalents | $116.2M | $52.8M | $9.7M |
| Marketable Securities | — | $45.4M | $39.4M |
| Prepaid Expenses | — | $2.8M | $2.6M |
| Other Current Assets | $4.2M | $0 | $0 |
| Long-Term Assets | $19.9M | $18.9M | $16.0M |
| PP&E (Net) | $6.6M | $6.4M | $4.5M |
| Operating Leases | $12.3M | $11.5M | $10.6M |
| Other LT Assets | $1.0M | $1.1M | $985.0K |
| Total Assets | $140.3M | $119.9M | $67.7M |
| Current Liabilities | $8.4M | $7.3M | $7.7M |
| Accounts Payable | $1.7M | $1.3M | $1.2M |
| Current Leases | $838.0K | $1.0M | $1.2M |
| Other Current Liab | $16.0K | $0 | $0 |
| Long-Term Liabilities | $20.9M | $14.6M | $13.4M |
| LT Operating Leases | — | $13.8M | $12.6M |
| Other LT Liab | — | $830.0K | $787.0K |
| Total Liabilities | $29.2M | $21.9M | $21.0M |
| Shareholders' Equity | $111.0M | $98.0M | $46.7M |
| Paid-In Capital | $172.7M | $230.7M | $242.6M |
| Retained Earnings | $-61.6M | $-132.7M | $-195.9M |
| AOCI | — | $10.0K | $50.0K |
| Treasury Stock | $6.0M | — | — |
| Total L&E | $140.3M | $119.9M | $67.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $5.2M | $-71.1M | $-63.2M |
| Non-Cash Adjustments | $-68.6M | $17.5M | $14.3M |
| Working Capital Changes | $2.2M | $-8.7M | $-1.1M |
| Cash from Operations | $-61.2M | $-62.3M | $-50.0M |
| Capital Expenditures | — | $1.7M | $180.0K |
| Cash from Investing | $-5.4M | $-45.8M | $6.9M |
| Cash from Financing | $9.1M | $44.7M | $8.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-57.4M | $-63.4M | $-43.1M |
| Beginning Cash | $174.6M | $117.1M | $53.8M |
| Ending Cash | $117.1M | $53.8M | $10.7M |
Frequently Asked Questions
How does Vicarious Surgical Inc. make money?
The company operates primarily in the medical technology sector, focusing on the development of a fully autonomous robotic surgical system designed for remote operation. Current financials indicate minimal commercial revenue with significant investment directed toward research and development of proprietary software and hardware platforms. The business model relies heavily on strategic partnerships and grants to fund innovation before scaling commercial sales.
What are the main risks for RBOT?
The company faces substantial commercialization risk as it has not yet generated meaningful revenue from product sales to support its massive cash burn rate. Dependence on external funding sources is critical given the significant accumulated deficit and negative operating cash flow over the last three years. Regulatory approval pathways for autonomous medical devices are lengthy and uncertain, potentially delaying market entry and revenue recognition. The specialized nature of the technology limits the total addressable market if adoption rates by hospitals remain low due to high capital expenditure requirements.
What is RBOT's competitive advantage?
Vicarious Surgical possesses unique intellectual property in the field of autonomous telesurgery, allowing remote surgeons to perform procedures from distant locations without direct physical presence. The company's fully autonomous system eliminates the need for a local surgeon to operate the console during the procedure, reducing costs and increasing access in rural areas. Proprietary software algorithms and proprietary robotic hardware design provide a technological moat against competitors that rely on manual telepresence models.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.